Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0280570
Abstract: Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs… read more here.
Keywords: patient oop; oop costs; list price; sofosbuvir ... See more keywords
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2025.31.5.491
Abstract: BACKGROUND More than 10,000 rare diseases affect more than 30 million Americans, nearly 70% of which manifest in childhood. The drug development pipeline boasts hundreds of candidates for pediatric-onset rare disease, but little is known… read more here.
Keywords: pediatric onset; rare disease; list price; pipeline ... See more keywords